Trials / Sponsors / Immune-Onc Therapeutics
Immune-Onc Therapeutics
Industry · 4 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Advanced Solid Tumor | Phase 1 | 2022-09-09 |
| Completed | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors Solid Tumor, Adult | Phase 1 | 2022-04-11 |
| Completed | First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Solid Tumor, Adult | Phase 1 | 2021-09-30 |
| Completed | IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML AML With Monocytic Differentiation, CMML | Phase 1 | 2020-09-14 |